Zhejiang Starry Pharmaceutical (603520.SH) plans to acquire a 20% stake in Rui Shi Pharmaceutical for 10 million yuan to increase CMO production capacity.
Si Taili (603520.SH) announced that the company plans to acquire 20.00% of the equity of Jiangsu Ruishi Pharmaceutical Co., Ltd. (referred to as "Ruishi Pharmaceutical") held by Ms. Li Yongping for 10 million yuan.
Zhejiang Starry Pharmaceutical (603520.SH) announced that the company plans to acquire 20.00% equity of Jiangsu Ruishi Pharmaceutical Co., Ltd. (referred to as "Ruishi Pharmaceutical") held by Ms. Li Yongping for 10 million yuan.
The announcement shows that Ruishi Pharmaceutical has established deep cooperation with well-known domestic and foreign CDMO companies and first-line innovative drug companies. Its product line covers a variety of core raw materials such as small molecule compounds, amino acids and their derivatives, dedicated to providing stable and reliable high-quality material support for customers from early drug research and development to application stage, accelerating the process of new drug development. Through this transaction, it will benefit the company's CMO capacity enhancement and the development of downstream customers.
Related Articles
Asia Financial (00662) announced that its net profit for the year 2025 is approximately HK$1.053 billion, a year-on-year increase of 62.73%. The final dividend per share is 16 Hong Kong cents.
MORIMATSU INTL (02155): Hiroaki Kurai appointed as independent non-executive director
On March 23, LE SAUNDA (00738) spent HKD 201,600 to repurchase 576,000 shares.
Asia Financial (00662) announced that its net profit for the year 2025 is approximately HK$1.053 billion, a year-on-year increase of 62.73%. The final dividend per share is 16 Hong Kong cents.
MORIMATSU INTL (02155): Hiroaki Kurai appointed as independent non-executive director
On March 23, LE SAUNDA (00738) spent HKD 201,600 to repurchase 576,000 shares.
